



Regulus Therapeutics Inc.
Investor Relations Department
10614 Science Center Dr
San Diego, CA 92121
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: RGLS

Last Trade:	0.85
Trade Time:	4:00 PM ET Aug 21, 2017
Change:	0.02 ↑ (+2.457%)
Day Range	0.79 - 0.85
52-Week Range	0.82 - 3.65
Volume	575,808

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting *microRNAs*. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced *microRNA* therapeutics pipeline complemented by a maturing *microMarkers*SM biomarkers platform and a rich intellectual property estate to retain its leadership in the *microRNA* field. Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting *microRNA*-122 for the tre... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 8, 2017
[Regulus to Present at the 2017 Webdush PacGrow Healthcare Conference](#)
- Aug 1, 2017
[Regulus Reports Second Quarter 2017 Financial Results and Recent Events](#)
- Jul 25, 2017
[Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares](#)
- Jul 25, 2017
[Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017](#)
- Jul 19, 2017
[Regulus Announces Pricing of Public Offering of Common Stock](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 3, 2017
[Annual Report \(10-K\)](#)
- Apr 28, 2017
[Proxy Statement \(DEF 14A\)](#)
- Aug 2, 2017
[Quarterly Report \(10-Q\)](#)
- May 5, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 2, 2016
[Quarterly Report \(10-Q\)](#)